Neuroptika

See Neuroptika

South Korea · Founded 2018 · $5.7M raised

Employees
1–10
Founded
2018
Business Model
B2B
Total Funding
$5.7M
Last Round
$2.7M Seed
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Neuroptika is a clinical-stage biotechnology company developing novel regenerative and neuroprotective therapies for ophthalmic diseases, with a primary focus on retinal degeneration. The company's pipeline includes NRO-CMK targeting neurodegenerative glaucoma via AAV-delivered CaMKII gene therapy, NRO-VTN targeting drusen formation in dry AMD, and an undisclosed program for diabetic retinopathy. Neuroptika's approach addresses unmet needs in conditions affecting hundreds of millions of patients globally where current treatments cannot halt or reverse optic nerve and retinal damage. The company has completed Phase 2 clinical trials for its lead corneal nerve regeneration asset and holds exclusive licenses from Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys.

Summary

Neuroptika is a Biotech company based in South Korea, founded in 2018. It has raised $5.7M in total across 2 rounds. Investors include KB Investment, Company K Partners and Woori Venture Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed Round
$2.7M

Sign up to see all 2 events

Funding, valuations, and company events, with amounts and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Neuroptika on Indexed.vc
<a href="https://indexed.vc/companies/neuroptika"><img src="https://indexed.vc/api/badge/company/neuroptika" alt="Neuroptika on Indexed.vc" width="260" height="76" /></a>